Literature DB >> 34298666

Albumin Nanostructures for Nucleic Acid Delivery in Cancer: Current Trend, Emerging Issues, and Possible Solutions.

Rama Prajapati1, Álvaro Somoza1.   

Abstract

Cancer is one of the major health problems worldwide, and hence, suitable therapies with enhanced efficacy and reduced side effects are desired. Gene therapy, involving plasmids, small interfering RNAs, and antisense oligonucleotides have been showing promising potential in cancer therapy. In recent years, the preparation of various carriers for nucleic acid delivery to the tumor sites is gaining attention since intracellular and extracellular barriers impart major challenges in the delivery of naked nucleic acids. Albumin is a versatile protein being used widely for developing carriers for nucleic acids. It provides biocompatibility, tumor specificity, the possibility for surface modification, and reduces toxicity. In this review, the advantages of using nucleic acids in cancer therapy and the challenges associated with their delivery are presented. The focus of this article is on the different types of albumin nanocarriers, such as nanoparticles, polyplexes, and nanoconjugates, employed to overcome the limitations of the direct use of nucleic acids in vivo. This review also highlights various approaches for the modification of the surface of albumin to enhance its transfection efficiency and targeted delivery in the tumor sites.

Entities:  

Keywords:  albumin; cancer; gene therapy; nanocarriers; surface modification

Year:  2021        PMID: 34298666     DOI: 10.3390/cancers13143454

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  1 in total

1.  BSA-PEI Nanoparticle Mediated Efficient Delivery of CRISPR/Cas9 into MDA-MB-231 Cells.

Authors:  Hossein Rahimi; Kasra Arbabi Zaboli; Jose Thekkiniath; Seyed Hossein Mousavi; Behrooz Johari; Mohammad Reza Hashemi; Hamed Nosrati; David Goldschneider; Agnes Bernet; Hossein Danafar; Saeed Kaboli
Journal:  Mol Biotechnol       Date:  2022-06-07       Impact factor: 2.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.